Prof Eggermont speaks with ecancertv at ESMO 2016 about results from the EORTC 18071 phase III trial of ipilimumab, an anti-CTLA 4 immune checkpoint inhibitor, as an adjuvant therapy for patients with high risk stage III melanoma.
Prof Eggermont describes the improved overall survival rate of five years, 11% high in the ipilumumab arm, as coming at the cost of immune related side effects associated with ipilimumab.
The results were published simultaneously to the conference in the New England Journal of Medicine.
ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.